Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:
“New 1L HCC Data from China!
HEPATORCH Trial (Phase 3):
Toripalimab + Bevacizumab vs Sorafenib
Median OS: 20.0 vs 15.3 mo | HR 0.76
Median PFS: 5.8 vs 3.7 mo | HR 0.69
ORR: 25.6% vs 5.5%
Grade ≥3 AEs: HTN (38%), Proteinuria (19%)
Now let’s compare With previous data in same space. Cross trial comparison is a SIN in oncology But that’s the ONLY sin we all do.”
More posts featuring Amol Akhade on OncoDaily.